Endo International plc, of Dublin, said based on an Aug. 11 discussion with the FDA, it is withdrawing its supplemental NDA relating to specific abuse-deterrent labeling for Opana ER (extended-release oxymorphone) without prejudice to re-filing. The company said it plans to continue collecting and analyzing epidemiological data. Opana ER is an opioid agonist approved for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatment options are inadequate.